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REPORT
Deleterious Mutation in the Mitochondrial Arginyl–Transfer RNA
Synthetase Gene Is Associated with Pontocerebellar Hypoplasia
Simon Edvardson, Avraham Shaag, Olga Kolesnikova, John Moshe Gomori, Ivan Tarassov,
Tom Einbinder, Ann Saada, and Orly Elpeleg
Homozygosity mapping was performed in a consanguineous Sephardic Jewish family with three patients who presented
with severe infantile encephalopathy associated with pontocerebellar hypoplasia and multiple mitochondrial respiratory-
chain defects. This resulted in the identification of an intronic mutation in RARS2, the gene encoding mitochondrial
arginine–transfer RNA (tRNA) synthetase. The mutation was associated with the production of an abnormally short RARS2
transcript and a marked reduction of the mitochondrial tRNAArg transcript in the patients’ fibroblasts. We speculate that
missplicing mutations in mitochondrial aminoacyl-tRNA synthethase genes preferentially affect the brain because of a
tissue-specific vulnerability of the splicing machinery.
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Of the 85 subunits that form the mitochondrial respira-
tory chain, 13 are synthesized within the mitochondria
and depend on a separate mitochondrial translation sys-
tem. This apparatus consists of 2 ribosomal RNA (rRNA)
and 22 tRNA transcripts encoded by the mitochondrial
genome and a large set of nuclear-encoded ribosomal
proteins, aminoacyl-tRNA synthetases, tRNA modification
enzymes, and translation factors. For the past 2 decades,
1130 pathogenic mutations in the mitochondrial tRNA
and rRNA genes have been registered in the Mitomap da-
tabase. The clinical phenotypes range from mild, late-on-
set disorders, such as age-related sensorineural hearing
impairment, ocular myopathy, and diabetes mellitus, to
devastating and usually fatal infantile disorders, such as
Leigh syndrome.
More recently, defects in a small number of nuclear-
encoded components of the mitochondrial translation
machinery, including three translation factors (EFG1, EF-
Ts, and EF-Tu)1–3 and a single ribosomal protein,4 were
identified. The patients presented in early infancy with
encephalopathy and marked lactic acidosis accompanied
by cardiomyopathy and liver failure, with mutations of
EF-Ts and EFG1, respectively. Onset during childhood and
lack of significant acidosis were characteristic for patients
with mutations in the tRNA modification factor PUS15
who presented with myopathy and anemia. Slowly pro-
gressive disease was also described in patients with leu-
kodystrophy due to mutations in the mitochondrial as-
partyl-tRNA synthethase.6
We investigated three patients, the products of a Se-
phardic Jewish consanguineous marriage, who had in-
fantile encephalopathy and a putative defect in mito-
chondrial translation. Patient II-2, the second child of the
parents, was a girl born at 41 gestational wk by uncom-
plicated vaginal delivery after an uneventful pregnancy.
Her Apgar scores were 8 at 5 min and 9 at 10 min, birth
weight was 2,700 g, length was 51 cm, and head circum-
ference was 34 cm. Physical examination at several hours
of age revealed generalized hypotonia and poor sucking.
Brain magnetic resonance imaging (MRI) at age 3 d (fig.
1a) disclosed cerebellar and vermian hypoplasia but nor-
mal brain volume. Recurrent apnea since age 1 wk was
controlled by phenobarbital, but intractable seizures that
started at age 2 mo were resistant to multidrug therapy.
She failed to thrive because of poor sucking and gastroe-
sophageal reflux. After the insertion of gastrostomy tube
and funduplication, her weight gain became satisfactory,
but microcephaly became evident (at age 1 year, head cir-
cumference was 40 cm). The patient did not attain any
developmental milestones, and her muscle tone became
spastic. The results of repeated fundoscopic examinations
were normal. Serial brain MRI revealed progressive atro-
phy of the cerebellum, pons, cerebral cortex, and white
matter (fig. 1). The patient died at age 16 mo.
Thorough investigations aimed toward elucidation of
the severe neurological disease of patient II-2 performed
throughout her life, including nerve and skin biopsy for
inclusion bodies, did not disclose any abnormality. Spe-
cifically, levels of creatine kinase, plasma lactate, and
amino acids; findings from liver and renal function tests,
isoelectrofocusing of transferrins, karyotype analysis,
and FISH analysis for Prader-Willi and Miller-Dieker syn-
dromes; and acylcarnitine profile and urinary organic acid
profile were all normal. Enzymatic investigations in leu-
kocytes excluded Krabbe disease, metachromatic leuko-
dystrophy, GM1 gangliosidosis, mannosidosis, and Tay
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Figure 1. Brain MRI of patient II-2 (a–e) and patient II-5 (f–h). a, Sagittal T1-weighted image of patient II-2 obtained at age 3 d,
showing hypoplasia of the cerebellum and the vermis, with progression at 5 mo (d). Brain volume was relatively preserved at age 3 d
(a) but decreased at age 5 mo (b) and at age 9 mo (c), mainly because of white-matter depletion (panels b and c are axial T2-weighted
images). e, Axial T2-weighted image of patient II-2 obtained at age 9 mo, showing severe pontine atrophy. Midsagittal (f) and coronal
(g) T1-weighted images of patient II-5 obtained at age 3 mo show hypoplasia of the cerebellum and the vermis. h, Axial T2-weighted
images disclosing some parenchymal loss, mostly of the white matter, with relative sparing of the basal ganglia and cortex.
Sachs disease. Findings from echocardiogram, electromyo-
gram, and the nerve conduction velocity test were normal,
but electroencephalography (EEG) repeatedly disclosed
generalized epileptic activity with attenuation, which was
more prominent over the right hemisphere. In homoge-
nate of skeletal muscle obtained at age 5 mo, the activity
of cytochrome c oxidase (complex IV) was 0.65 mmol/min/
g protein (controlSD 2.800.52), that of succinate:cy-
tochrome c reductase (complexes II and III) was 0.18 mmol/
min/g protein (0.700.23), that of NADH:cytochrome c
reductase (complexes I and III) was 0.06 mmol/min/g pro-
tein (1.020.38), that of NADH dehydrogenase (complex
I) was 13.25 mmol/min/g protein (35.487.07), and that
of succinate dehydrogenase (complex II) was 0.77 mmol/
min/g protein (1.000.53) (Dr. S. Shanske, College of Phy-
sicians and Surgeons, Columbia University, New York).
Patient II-4, the fourth child in the family, was a boy
who was markedly hypotonic and lethargic since birth.
He was difficult to arouse and fed poorly because of in-
adequate sucking. Findings from brain ultrasound at age
3 d were normal, plasma lactate was 3 mM (normal !2.4
mM), and levels of creatine kinase, amino acids, very-long-
chain fatty acids, and phytanic and pristanic acids and
urinary organic acid profile were all normal. No devel-
opmental milestones were reported, and the patient was
found dead in his crib at age 7 wk. A skin biopsy sample
for fibroblast culture was obtained immediately after
death. The enzymatic activities of the mitochondrial re-
spiratory-chain complexes I–V in mitochondria isolated
from the fibroblasts were determined by standard spec-
trophotometric methods.7 Complex I activity normalized
for citrate synthase activity was reduced to 60% of the
control mean, but complex II–IV activity was within the
normal range.
Patient II-5, the fifth child in the family, was a girl born
at term by vaginal delivery after an uneventful pregnancy.
Of note, fetal brain sonography at 20 wk gestation dis-
closed normal brain anatomy. Birth weight was 2,650 g,
and head circumference was 32.2 cm. A thorough neu-
rological examination on the 1st d of life produced normal
findings, but a single apneic episode was noted on the 2nd
d of life. At age 3 wk, poor feeding, lethargy, and gener-
alized hypotonia became evident; results of fundoscopy
and EEG were normal. Pharyngeal muscle incoordination
was demonstrated by fiber-optic examination; thereafter,
normal weight gain was sustained by nasogastric tube
feeding. Repeated episodes of respiratory failure, initially
attributed to an insufficient respiratory drive, were re-
solved by tracheostomy with restoration of spontaneous
breathing. At age 4 mo, she experienced generalized sei-
zures, and her head growth was arrested. Physical exam-
ination revealed a pale, ill-appearing child with limb spas-
ticity, bilateral elbow contractures, and truncal hypotonia.
She responded to auditory stimuli but had no meaningful
interaction with her surroundings. Brain MRI performed
at age 3 mo revealed general atrophy, and the pons and
the cerebellum were the most affected (fig. 1f–1h). Plasma
lactate level was normal, but cerebrospinal fluid (CSF) lac-
tate level was 3–4 mM (normal !2 mM). There was no
indication of any extracerebral involvement. Specifically,
results of renal and liver function tests, levels of creatine
kinase, plasma amino acids profile, carnitine and acylcar-
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Figure 2. The family members’ haplotype along the critical region on chromosome 6. The polymorphic microsatellite markers and their
chromosomal locations (in Mb) are given in the upper left panel. The SNPs bordering the homozygous region are given above and below
the panel. The linked region is bordered by bold lines.
nitine levels, and urinary organic acids profile were nor-
mal. In muscle mitochondria obtained at age 1 mo, the
activity of complex IV was reduced to 50% of the control
mean. The activities of all other complexes were normal.
The parents and their daughters II-1 and II-3, aged 11 and
6 years, respectively, were healthy.
The marked reduction of complex I, III, and IV activities
in patient II-2 muscle and the relative preservation of ac-
tivity in complex II—the only complex that is solely en-
coded by the nuclear genome—suggested a defect in the
synthesis of the mtDNA-encoded proteins. The ratio of
mtDNA to nuclear DNA in the muscle of patient II-5, de-
termined by real-time PCR, was 340% of the control mean,
ruling out mtDNA depletion. A defect in mtDNA tran-
scription was investigated by determination of the abun-
dance of the transcripts of the 12S and the 16S rRNA genes
and the mRNA of the heavy strand–encoded COX2 gene
in cultured fibroblasts. This analysis disclosed a slight re-
duction of both rRNA transcripts—12S rRNA was 70% and
16S rRNA was 65% of the control—precluding a defect in
one of the ∼70 mitochondrial ribosomal proteins, which
would lead to a severe reduction of only one of the rRNA
transcripts.4 The COX2 mRNA was also slightly reduced
(65% of the control) in fibroblasts.
To localize the mutated gene, homozygosity mapping
was performed. Genomic DNA was extracted from fibro-
blasts of individuals II-2 and II-4, from the cord blood of
individual II-5, and from the blood samples of the parents
and the two healthy sisters. All experiments involving
DNA from the patients, their relatives, and healthy con-
trols and patients’ cells were performed with informed
consent and were approved by the Hadassah Ethical Re-
view Committee (number 26-160905) and by the Supreme
Helsinki Committee of the Israeli Ministry of Health
(number 920050420).
Homozygous regions were searched in the DNA sam-
ples of patients II-2 and II-4 with use of the Affymetrix
Human Mapping 50K Array Xba240. The chip allowed
genotyping of SNPs with an average distance of ∼50 kb
between the markers. Digestion with Xba240, ligation of
the adaptor, and amplification with a generic primer that
recognizes the adaptor sequence were followed by frag-
mentation, end labeling, and hybridization to the chip in
accordance with the manufacturer’s instructions. Homo-
zygous regions 15.0 cM8 were manually detected. Only
two homozygous regions were shared by patients II-2 and
II-4: on chromosome 5, 155.24–172.22 Mb (bordered by
markers rs2116739 and rs793027) and, on chromosome
6, 82.32–111.83 Mb (bordered by markers rs4448140 and
rs1989574). This latter region was narrowed by individual
II-1, who shared homozygosity at the polymorphic mi-
crosatellite markers D6S1546 and D6S268 with her af-
fected sibs (fig. 2). Investigation of the DNA extracted from
the cord blood of patient II-5 revealed that she had a hap-
lotype similar to that of her healthy sister II-1, by use of
markers spanning the genomic region on chromosome 5
(D5S2049, D5S422, D5S2040, D5S2050, D5S671, D5S400,
and D5S425). However, a haplotype identical to those of
patients II-2 and II-4 was found along the chromosome 6
critical region (fig. 2). Within this 22.46-Mb region on
chromosome 6, there were 103 ORFs. None of these was
annotated mitochondrial, but RARSL, the arginyl-tRNA
synthetase–like gene, was predicted mitochondrial (52%
probability) by PSORT II prediction software. The gene
consists of 20 exons, which code for 578 aa. We deter-
mined the sequence of each exon and its flanking intronic
860 The American Journal of Human Genetics Volume 81 October 2007 www.ajhg.org
Figure 3. IVS25 arg mutation, which causes exon 2 skipping.
RARS2 exon 2–IVS2 splice-junction sequence of the patient (a)
and his mother (b). The mutation site is indicated by an arrow.
c, RARS2 cDNA showing exon 2 skipping at the patient sample.
Exons 1 and 3 are indicated. d, RARS2 cDNA of the mother showing
heterozygosity for the wild-type and the mutant transcripts. e,
PCR amplification products of RARS2 cDNA encompassing the first
three exons. Lane 1, patient; lane 2, mother; lane 3, control. A
100-bp ladder was loaded in the left lane.
Figure 4. Quantitative and aminoacylation analysis of tRNAArg
in fibroblasts. a, Quantitative analysis of tRNAArg and tRNALeu in
the patient and control (C2.5) by northern hybridization. Equal
amounts of control and patient RNA were analyzed. b, Amino-
acylation: results of the hybridization after separation in acid
conditions. AAp aminoacylated form; DAp deacylated form. The
control of fully deacylated tRNA (daControl) was obtained by in-
cubation of the RNA at 50C (pH 9.0) for 10 min.
sequences and identified three homozygous substitutions,
K568K (aaaraag), R291K (agaraaa), and IVS25 (arg) (fig.
3a). The K568K substitution did not interfere with any
splicing-enhancer element, as predicted by the ESEfinder
program9; similarly, with use of the SIFT software, the
R291K substitution was not predicted to be pathogenic.
The three patients were homozygous for the IVS25 arg
substitution, and the parents and their two healthy daugh-
ters were carriers. We sequenced the exon 2–IVS2 junction
in 105 anonymous individuals of Sephardic Jewish origin
and did not find any carriers for this substitution.
We next extracted total RNA from cultured skin fibro-
blasts of individual II-4 and from the blood of his mother,
I-1, and amplified the RARS2 cDNA (GenBank accession
number NM_181406.2) in four overlapping fragments.
The patient’s major transcript lacked exon 2 (fig. 3c), but
a faint, normal-sized fragment was also seen (fig. 3e); the
mother had two transcripts of equal abundance, a normal
one and a shorter one lacking exon 2. Because exon 2
consists of 74 nt, its skipping is predicted to cause a frame-
shift, abolishing the enzymatic activity entirely. We there-
fore set out to determine the extent of aminoacylation
and the stability of the mitochondrial tRNAArg transcript
in the patient fibroblasts. Total RNA was isolated in acid
conditions10 from the patient and control fibroblasts and
was separated on a 10-cm-long 10% denaturing (8 M urea
and Tris/borate/EDTA) polyacrylamide gel (PAAG). Quan-
titative northern hybridization was performed11 with
the following oligonucleotide probes: nucleotides 10421–
10441 (GAGTCGAAATCATTCGTTTTG) for the mitochon-
drial tRNAArg and nucleotides 3275–3293 (CAGTCAGAGC-
TTCAATTCC) for the mitochondrial tRNALeu. The signals
were quantified by phosphorimager (FLA 5100 [Fuji]) and
were calculated by the MutiGauge Software (Fuji). The
analysis of aminoacylation level in vivo was performed by
hybridization with the same probes after separation of the
RNA on 6.5% denaturing PAAG (20 cm long) in 0.1 M Na-
acetate (pH 4.8).10 A striking reduction in the amount of
the mitochondrial tRNAArg was found in the patient fibro-
blasts, and the tRNAArg:tRNALeu ratio was 6% of the con-
trol. In contrast, the residual tRNAArg transcript was almost
fully acylated (fig. 4). These results confirm that the RARSL
gene encodes a product with mitochondrial arginyl-tRNA
synthetase activity, as predicted in silico.12 The results
strongly suggest that uncharged mitochondrial tRNAArg
transcripts become unstable. The minute amount of the
wild-type RARS2 transcript probably accounts for a resid-
ual tRNAArg aminoacylation capacity in the patient fibro-
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blasts and for the relatively high residual respiratory-chain
activity in these cells.
Until now, deficiency of the mitochondrial tRNAArg syn-
thetase had been identified only in yeast.13 As expected,
mitochondrial protein synthesis was impaired in the mu-
tants, and the enzymatic activities of the mitochondrial
respiratory-chain complexes III, IV, and V were markedly
reduced.
In spite of the large number of mutations reported in
mitochondrial tRNA genes, a defect in tRNAArg was seldom
described. An 8-year-old patient with progressive enceph-
alopathy manifested by moderate retardation, nystagmus,
delayed dysarthric speech, and clumsiness was found to
carry an arg mutation at position 10438 of the mtDNA.
The mutation changed a conserved nucleotide that flanks
the tRNAArg anticodon sequence, and the mutant load was
high in muscle (88%) and lower in blood (73%). In plasma,
but not in CSF, the lactate level was slightly elevated. In
muscle, complex IV activity was reduced, but complexes
I, IIII, and IIIII were normal.14 Mice with a small genomic
insertion in the D-loop of the mitochondrial tRNAArg gene
were deaf,15 and cell lines harboring the mutation pro-
duced abnormally elevated reactive oxygen species.16 The
mechanism is unclear, since no significant difference in
the relative amounts of respiratory-chain complexes es-
timated by western blotting was found in these cell lines.
The milder phenotype in humans and mice with mito-
chondrial tRNAArg mutations is probably the result of sig-
nificant residual mitochondrial translation activity, attrib-
uted to the heteroplasmic nature of the mutation in
humans and to the low pathogenicity of the mutation in
mice.
A major question raised by our finding is the tissue spec-
ificity of the symptoms. Even after 16 mo of life, the symp-
toms of patient II-2 were still confined to the CNS, and
neither the heart nor the liver, both energy-demanding
tissues, were affected. The RARS2 defect is unlikely to be
compensated by RARS1, because the encoded cytoplasmic
arginine-tRNA synthetase lacks mitochondrial targeting
sequence; furthermore, it is generally accepted that cy-
toplasmic tRNAs, even when properly charged, do not tra-
verse the mitochondrial inner membrane in humans.17,18
We therefore speculate that the leaky nature of the mu-
tation allows for the synthesis of a small amount of wild-
type RARS2 transcript in most tissues, similar to fibro-
blasts. The production of the wild-type transcript in such
circumstances is dependent on the splice-site score of the
wild-type exon-intron junction, the presence and conser-
vation of exonic splicing-enhancer domains, and the tis-
sue concentration of the splicing factors. It is of note that
the 3′ splice site of exon 2 of the wild-type RARS2 gene
deviates markedly from the consensus—that is, its splicing
score is very low (Splice Site Score Calculation).
Very recently, mutations in the mitochondrial aspartyl-
tRNA synthethase (DARS2) gene were reported in patients
with leukodystrophy with brain stem and spinal cord in-
volvement.6 Similar to our patients, there was no extra-
cerebral involvement. Nearly all the patients carried a mu-
tation involving a stretch of T and C residues just upstream
of exon 3 on one of the DARS2 alleles. This mutation was
predicted to result in skipping of exon 3, affecting, as in
our case, an a priori weak splice site. We speculate that
one of the splicing factors, required for the promotion of
exon inclusion in both cases, is present in relatively low
concentration in the brain.
Our patients presented with pontocerebellar hypoplasia
(PCH) already evident at age 3 d. There are at least five
types of nonsyndromic, autosomal recessive PCH. In ad-
dition, this hindbrain abnormality has been reported in
association with established syndromes, congenital mus-
cular dystrophies, lissencephaly syndromes, chromosomal
abnormalities, defects in glycosylation of proteins, organ-
ic acid disorders, and mitochondrial respiratory-chain de-
fects.19,20 In view of the very mild mitochondrial stigmata
(slight elevation of CSF lactate), it is possible that some
of the autosomal recessive PCHs are in fact the result of
missplicing mutations in the RARS2 gene or in other mi-
tochondrial aminoacyl-tRNA synthethase genes.
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